# A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

> **NCT04481607** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 96 (estimated)

## Conditions studied

- Advanced Solid Tumor or Hematologic Tumor

## Interventions

- **DRUG:** TQB3454

## Key facts

- **NCT ID:** NCT04481607
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-24
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2022-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04481607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04481607, "A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04481607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*